Clinical reference Biomarker Directory
Back to directory

CSF1

Emerging

CSF1 overexpression drives tenosynovial giant cell tumor, now treatable with two different CSF1 receptor inhibitor drugs.

Also known as CSF1 M-CSF macrophage colony-stimulating factor
In plain language

CSF1 is a signaling protein that, when overproduced due to a gene abnormality, drives a rare joint tumor by recruiting certain immune cells. Two different drugs now exist that block this pathway directly, with the newest approved in 2025.

Biomarker & context

Colony stimulating factor 1 (CSF1, also called M-CSF) is a cytokine that regulates the production, differentiation, and function of macrophages by signaling through the CSF1 receptor (CSF1R).

What it indicates

CSF1 gene translocation and overexpression drives tenosynovial giant cell tumor (TGCT), a rare, locally aggressive joint tumor, by recruiting CSF1R-expressing macrophages into the tumor mass.

Diagnosis & clinical testing

Diagnosis of TGCT is primarily via imaging and tissue biopsy showing characteristic CSF1-driven macrophage infiltration; CSF1 itself is not a standard blood test but underlies the molecular rationale for targeted therapy.

Guiding treatment

This led to pexidartinib (FDA-approved 2019) and, very recently, vimseltinib (FDA-approved 2025) — a second, more selective CSF1 receptor inhibitor for TGCT patients who aren't good surgical candidates, representing a genuinely active and evolving area of targeted oncology drug development.

Clinical significance

A 2025 second-generation CSF1R inhibitor (vimseltinib) reflects an actively evolving targeted therapy area.

References
  1. FDA. (2025). Vimseltinib Approval for Tenosynovial Giant Cell Tumor.
  2. General oncology reference literature on CSF1/CSF1R pathway in TGCT.